IBT remains differentiated to peers, offering exposure to the explosive potential of innovation in healthcare...

Dividend culture as we knew it is dead, according to Kepler's David Johnson, but investment trusts offer a solution...

IBT has had a change of management - but no change of strategy…

The pandemic has boosted secular growth drivers behind healthcare as an investment theme...

Download the presentation and listen to the audio from our 'Ideas for your ISA' Spring Conference on 03 March...

IBT offers a differentiated way to access strong growth prospects at an undemanding valuation...

Slides and audio from our event focused on alternative routes to a reliable income…

View the presentation and listen to the audio from our 'Alternatives for Income Investors' event on 29 September...

IBT offers a differentiated exposure to a secular growth theme complemented by a solid yield…

Is there something fishy about a trust paying dividends from capital?

Two of our analysts discuss the growing trend for companies to pay an income out of capital…

A highly experienced management team and a flexible portfolio of quoted and unquoted biotechnology stocks, with a yield target of 4% of NAV...

We discuss the opportunity as biotech stocks trade at record low valuations, despite strong prospects for the sector...

Chairman of International Biotechnology Trust, John Aston, explains how his unusual background in both biotechnology and banking come together on the trust...

Carl Harald Janson explains how his experiences in science and business blend seamlessly in his management of International Biotechnology Trust...

Five years on from the appointment of a new manager, this US-focused biotech trust has seen its fortunes transformed...

Some investment trust premiums have been stretched to eye-watering levels. Have investors been enjoying themselves in the sun too much? We try to rationalise current levels and suggest alternatives...

A well-resourced biotechnology fund that has produced annualised returns of +18% under the current manager, offering a yield of 4%...

We scour the investment trust universe for trusts offering chunky yields on a discount...

CPD certificate, speaker presentations and slides...

Searching for the Tesla of tomorrow…

As equity valuations continue to defy logic, we identify the trusts least correlated to their fortunes...

Carl Harald Janson, once dubbed 'the world's best biotech manager' by Bloomberg, tells us what he thinks lies in store for the sector...

We highlight various routes to US exposure for those who are not sure how much faith they place in the 'Trump Bump'...

Our analysis shows that technology trusts are far less risky than the returns they have generated suggest...